Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Johnson & Johnson (J&J) has started a Phase I/IIa clinical trial of its Covid-19 vaccine candidate, Ad26.COV2.S, in healthy volunteers across the US and Belgium.
The first-in-human trial comes after the vaccine candidate showed promise in preclinical studies, where the product was able to trigger a immune response against SARS-CoV-2.
This immune response involves the generation of neutralising antibodies that were able to prevent subsequent infection and provide complete or near-complete protection in the lungs of non-human primates (NHPs).